Remibrutinib Dose B clinical trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

This study is testing a new medicine, remibrutinib, for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). Researchers want to see if it's safe and effective compared to a dummy pill.